(CPH) Cipher Pharmaceuticals - Ratings and Ratios

Cipher Pharmaceuticals Inc. (TO:CPH) is a specialty pharmaceutical company focused on developing and commercializing generic and innovative therapies. The companys product portfolio includes Epuris (isotretinoin), a treatment for severe acne; Actikerall, a topical solution for actinic keratosis; Ozanex for impetigo; Vaniqa, a cream for managing unwanted facial hair; Durela, an opioid analgesic; Brinavess for atrial fibrillation; and Aggrastat, a cardiovascular drug. Licensed products include Absorica for acne, Lipofen for cholesterol management, and Conzip for chronic pain. The pipeline features MOB-015 (terbinafine) for onychomycosis, CF-101 for psoriasis and rheumatoid arthritis, and DTR-001, a tattoo removal cream.

Founded in 2000 and headquartered in Mississauga, Canada, Cipher Pharmaceuticals has established itself in the pharmaceutical sector with a mix of branded and generic offerings. The companys strategic focus on dermatology and pain management aligns with growing healthcare demands. Their pipeline, particularly MOB-015 in Phase 3, shows promise for future growth.

Based on the technical and fundamental data, the 3-month forecast indicates potential undervaluation. The SMA20 (12.91) is below SMA50 (13.69) and SMA200 (13.16), suggesting a bearish trend. However, a strong RoE (16.04%) and reasonable P/E (13.89) highlight profitability and possible investor appeal. The low ATR (0.46) points to low volatility. Positive pipeline developments could act as catalysts for growth, making the stock attractive despite short-term trends.